Impetigo (limited number of lesions) (alternative agent): Topical: Apply a thin layer to affected area twice daily for 5 days (total treatment area should not exceed 100 cm2 total BSA) (Ref).
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
Refer to adult dosing.
Impetigo: Infants ≥2 months of age, Children, and Adolescents: Topical: Apply a thin layer to the affected area twice daily for 5 days. Note: Affected area may be up to 2% of the total BSA (not exceeding 100 cm2) for patients <12 years or up to 100 cm2 for patients ≥12 years.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
<1%, postmarketing, and/or case reports: Rosacea-like face eruption, seborrheic dermatitis
There are no contraindications listed in the manufacturer's labeling.
Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to ozenoxacin or any component of the formulation
Concerns related to adverse effects:
• Superinfection: Prolonged use may result in fungal or bacterial superinfection; discontinue use if superinfection occurs.
Other warnings/precautions:
• Appropriate use: For topical use only; not for oral, ophthalmic, intranasal, or intravaginal use.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Cream, External:
Xepi: 1% (30 g) [contains benzoic acid, propylene glycol]
No
Cream (Xepi External)
1% (per gram): $12.47
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Cream, External:
Ozanex: 1% (10 g) [contains benzoic acid, polyethylene glycol (macrogol), propylene glycol]
Topical: For topical use only; not for oral, ophthalmic, intranasal, or intravaginal use. Apply a thin layer to affected area; wash hands after application. Treated area may be covered with a sterile bandage or gauze dressing.
Topical: For external use only; not for oral, ophthalmic, intranasal, or intravaginal use. Apply a thin layer to affected area; wash hands after application. Treated area may be covered with a sterile bandage or gauze dressing.
Impetigo: Treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients ≥2 months of age
None known.
There are no known significant interactions.
Systemic absorption following topical application is negligible; exposure to the fetus is not expected.
It is not known if ozenoxacin is present in breast milk. However, systemic absorption following topical application is negligible and exposure to the breastfeeding infant is not expected.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.
Ozenoxacin is a quinolone antimicrobial that inhibits the bacterial DNA replication enzymes, DNA gyrase A, and topoisomerase IV.
Absorption: Negligible
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟